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Tolerogenic dendritic cells (DCs) work through silencing of differentiated antigen-specific
T cells, activation and expansion of naturally occurring T regulatory cells (Tregs), transfer
of regulatory properties to T cells, and the differentiation of naïve T cells into Tregs. Due
to an operational definition based on T cell activation assays, the identity of tolerogenic
DCs has been a matter of debate and it need not represent a specialized DC subset.
Human tolerogenic DCs generated in vitro using inhibitory cytokines, growth factors, nat-
ural immunomodulators, or genetic manipulation have been effective and several of these
tolerogenic DCs are currently being tested for clinical use. Ex vivo generated tolerogenic
DCs reduce activation of naïveT cells using various means, promote a variety of regulatory
T cells and most importantly, frequently show stable inhibitory phenotypes upon repetitive
maturation with inflammatory factors. Yet, tolerogenic DCs differ with respect to the phe-
notype or the number of regulatory mechanisms they employ to modulate the immune
system. In our experience, tolerogenic DCs generated using the biologically active form
of vitamin D (VD3-DCs), alone, or combined with dexamethasone are proficient in their
immunoregulatory functions. These tolerogenic DCs show a stable maturation-resistant
semi-mature phenotype with low expression of activating co-stimulatory molecules, no pro-
duction of the IL-12 family of cytokines and high expression of inhibitory molecules and IL-10.
VD3-DCs induce increased apoptosis of effectorT cells and induce antigen-specific regula-
toryT cells, which work through linked suppression ensuring infectious tolerance. Lessons
learned on VD3-DCs help understanding the contribution of different pattern-recognition
receptors (PRRs) and secondary signals to the tolerogenic function and how a cross-talk
between DCs and T cells translates into immune regulation.
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INTRODUCTION
Dendritic cells (DCs) comprise a network of professional antigen-
presenting cells (APC) throughout the body that orchestrate
responses to foreign antigens, while keeping in check autoreactive
T cells (Steinman et al., 2003a). DCs may initiate (inflammatory
DCs) or inhibit (tolerogenic DCs) the antigen-specific response.
Apart from preventing pro-inflammatory responses to antigens,
tolerance comprises active inhibition of existing effector immune
responses against a particular antigen. Depending on the origin of
this antigen, we may differentiate tolerance for self-antigens, for
antigens that originate in the environment or for alloantigens after
transplantation. Breaking tolerance may lead to pathology in all
cases: reaction of the adaptive immunity against alloantigen may
cause graft rejection; intolerance to foreign antigen predisposes to
allergy while immune responses against self-antigen may lead to
development of autoimmune disease.
There are different mechanisms by which immune tolerance
can be achieved: for instance, removal of pathogenic T cells, induc-
ing, or restoring a balance between pro- and anti-inflammatory
immunity or by action of regulatory T cells (Treg). A superior
ability of DCs to interact with naïve and experienced T cells and
contribute to all mechanisms of immune tolerance makes these
attractive candidates for tolerance induction strategies. Tolero-
genic DCs prevent the destructive action of self-reactive T cells
that had escaped the selection in the thymus, by mechanisms of
peripheral tolerance (Steinman et al., 2003a). Stimulation of Th1
and/or Th2-type of the immune response, which sometimes bal-
ances the destructive immunity, is also critically dependent on
action of DCs (Singh et al., 1999; Kidd, 2003; Amsen et al., 2004).
Finally, DCs and Treg are engaged in active dialog and critically
depend on each other’s function. Induction and maintenance of
Treg depends on DCs while Treg employ their regulatory action
through direct interaction with DCs, in addition to affecting effec-
tor T cells (Vendetti et al., 2000; Salcido-Ochoa and Lechler, 2002;
Pasare and Medzhitov, 2003; Steinman et al., 2003b).
Tolerogenic mechanisms essentially employ the antigen-
presenting function of DCs, in which co-stimulatory molecules
play an important role. Activation of T cells requires that at least
two signals are transferred by the APC: (Steinman et al., 2003a)
antigen in the form of peptide bound to MHC molecules (Amsen
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et al., 2004), co-stimulation, especially provided by molecules of
the B7 and TNF-receptor families. In addition, cellular adhesion
molecules and cytokines support activation of T cells that have
made a productive interaction with antigen-presenting- and co-
stimulatory molecules. For instance, inflammatory DCs produce
and present IL-2 to naïve T cells to promote their activation
(Granucci et al., 2002; Wuest et al., 2011), cytokines of the IL-
12 family and IL-4 skewing T cells into a T helper-1 (Th1) or
T helper-2 (Th2) polarized phenotype (Kalinski et al., 1999), and
DCs secrete IL-10,TGFβ, IL-35,or TNF,which promote generation
of regulatory T cells (Kushwah and Hu, 2011). Finally, stimulated
T cells may be endowed with tissue-specific homing capacities
as a “fourth” signal delivered by APC to T cells (Campbell and
Butcher, 2002; Villablanca et al., 2008). The quantity and quality
of the distinct signals delivered by APC determine the outcome
of the ensuing T cell response and the ability of DCs to activate
a strong effector cell response has been vastly appreciated. How-
ever, DCs are also crucial in downregulation and tolerization of
the adaptive immune system and apart from being able to sense
various danger signals in inflammation, DCs integrate tolerogenic
signals originating from peripheral or lymphoid tissues, support-
ing the maintenance of immune homeostasis and avoidance of
T cell autoreactivities (Steinman et al., 2003a; Yogev et al., 2012).
The primary function of DCs thus might be induction and main-
tenance of immune tolerance rather than activation of effector
responses.
Approaches to harness the immunoregulatory function of DCs
encompass the search for tolerogenic DCs in vivo and the in vitro
manipulation of monocyte-derived DCs to confer and secure their
tolerogenic function. The emerging concept implies that in vivo
tolerogenic DCs might not represent a specialized DC subset
but might embody a particular state of DC differentiation influ-
enced by a collection of tissue and environmental factors, making
it difficult to manipulate these cells in real time. The interplay
between resident DCs and naturally occurring Tregs (tTreg) from
the thymus likely reinforces the default tolerogenic state of DCs.
In vitro manipulation of monocyte-derived DCs has proven use-
ful and modulated DCs are being currently tested for clinical use.
In this review, we summarize our lessons learned using Vitamin
D3-treated DCs on the role of secondary signals in the genera-
tion of tolerogenic DCs and how these may induce and maintain
peripheral tolerance.
HETEROGENEITY OF TOLERANCE-INDUCING DENDRITIC
CELLS: DO TOLEROGENIC DENDRITIC CELLS REPRESENT A
DISTINCT SUBSET?
The highly increased awareness of the role of DCs in steering
the immune system and their possible clinical applications has
resulted in a wealth of information about the phenotypic het-
erogeneity of DCs. However, unequivocal interpretation of these
findings in developmental and functional terms has proven to be
difficult, especially because of the high turn-over of DCs, their
significant mobility between peripheral and immune organs, the
phenotypic volatility of these cells in response to environmen-
tal conditions, and the differences between strategies to endorse
tolerogenic capacity. The application of phenotypic labeling to
define DCs created confusion since many “new” DC types in
different organs were defined, without a clear view on the possible
developmental relationships between these and already known DC
types. To illustrate this: in human thymus, three distinct DC popu-
lations have been found up to five populations in lymph nodes and
tonsils and at least three populations in blood (Lewis and Reizis,
2012). The situation is similarly complex in mice, since up to six
different DC types were found in mouse lymph nodes and spleen
(Dominguez and Ardavin, 2010).
Understanding the in vivo function of these different DCs and
establishing the identity of tolerogenic DCs has consequently taken
a while. In general, two schools of thinking have arisen; one that
proposes tolerogenicity to be a functional property of DC at a par-
ticular (immature) stage in development and another that hypoth-
esizes that a specific tolerogenic DC lineage exists. In favor of the
first proposal, immature DC induce anergic T cells, T cells with
regulatory properties as well as T cells that secrete immunomod-
ulatory cytokines. However, the immature phenotype of DCs is
replaced by mature/inflammatory upon triggering in the periph-
ery by danger/inflammatory signals and migration to the lymph
nodes, making the tolerogeneicity of immature DCs a transient
phase that can hardly be controlled for therapeutic purposes.
Establishment of DCs with a“semi-mature”phenotype, represent-
ing cells that have been “matured” in the absence of inflammation,
has enabled definition of functional regulatory DCs with a sta-
ble phenotype (Lutz and Schuler, 2002). The phenotype of these
DCs may vary depending on the “tolerizing” signals they receive
but in general, semi-mature DCs are able to present antigens like
mature DCs but lack high level pro-inflammatory cytokine pro-
duction and their repetitive injection prevents autoimmunity in
experimental models.
The hypothesis that a specific lineage of DC induces tolerance
has been widely accepted as well (Coquerelle and Moser, 2010).
Studies demonstrating two types of DCs in the peripheral blood,
so called myeloid or conventional (cDCs) and plasmacytoid DCs
(pDCs), which had different origins and functions, supported the
notion that inflammatory and tolerogenic DCs are unrelated cells
with separate precursors. In mice, CD8 – cDCs and tissue-derived
cDCs are predominantly immunogenic. Most notably implicated
in tolerance induction are CD8+ cDCs (Yamazaki et al., 2008)
and pDCs (Nikolic et al., 2009), so these were logical candidates
for a special tolerogenic DC lineage in mice. However, CD8+ cDCs
are not only tolerogenic but also cross-present antigens and prime
CD8 T cells (Crozat et al., 2011). Similarly, the tolerogenic potential
of pDCs has been demonstrated in allergic inflammation in vivo
(Kool et al., 2009), but pDCs can also stimulate Th1 or Th2 immu-
nity and CD8 T cell responses. This indicates that both CD8+
cDCs and pDCs can perform distinct functions depending on the
sum of factors that had influenced their maturation and activa-
tion (Swiecki and Colonna, 2010; Takagi et al., 2011). Together
with the identification of a common precursor for cDC and pDC
in mice (Auffray et al., 2009), the notion of a separate tolerogenic
DC lineage became less plausible.
Since both cDC and pDC as found in blood, bone marrow,
or peripheral organs represent the immature stage of the cell,
the notion is that “immature” or migratory DCs (plasmacytoid
or conventional) are able to down-regulate immunity until they
encounter an activation stimulus and become immunostimulatory
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APC. This again strengthens the view that all DC are in principle
tolerogenic in steady state, unless triggered by a “danger signal” in
the inflammatory context. Therefore, a unifying platform allowing
both scenarios under particular conditions would be that by con-
ditioning during differentiation determines the functional plas-
ticity of DCs and their diversity in origin/phenotype has evolved
to enable the immune system to “sense” various danger signals
with different intensity leading to different functional outcomes
depending on the context (Figure 1).
HARNESSING TOLEROGENIC DCs FOR THERAPEUTIC
PURPOSES
Dendritic cells that mediate tolerance induction in vivo exist
without doubt. However, it is still debatable whether a particu-
lar function demonstrated in vitro may also be exerted in vivo.
Immune tolerance can be achieved through different mechanisms
and the experimental data from an in vivo system do not discern
whether a particular DC subtype employs one or more mecha-
nisms, or what other cells in the system might contribute. For
example, thymic DCs have been associated with selection of devel-
oping T cells, but a recently established mouse model lacking the
majority of DCs (DC-less mice) suggested that DCs are dispens-
able in thymic negative selection (Yogev et al., 2012). Yet, DCs
in the periphery remain essential in induction and maintenance
of peripheral tolerance, since DC-less mice are able to mount an
immune response but fail to regulate it and develop enhanced
EAE and progressive myeloproliferative disorders, resulting in
spontaneous fatal autoimmunity (Birnberg et al., 2008; Ohnmacht
et al., 2009; Yogev et al., 2012). The expression of the MOG auto
antigen in steady state DCs in the brain induced strong tolerance,
correlating with the increased expression of PD-1 on adaptive reg-
ulatory T cells (Yogev et al., 2012). Taken together, these studies
show: (i) that autoimmunity may be activated by other cells than
DCs; (ii) that DCs are essential for the maintenance of tolerance;
(iii) that DCs may act by enhancing adaptive regulatory T cells.
Human peripheral blood pDCs and a subtype of human blood
DCs that expresses CD141 (CD141+DCs) are believed to mediate
tolerance in vivo. Although, there is some phenotypic and func-
tional overlap between human and murine DCs, there are also
important differences that prevent straightforward translation of
findings between species. For example, while both human and
mouse pDCs selectively express TLR7 and TLR9, securing the abil-
ity to produce IFN-I in response to TLR7/9 ligation, human pDCs
do not produce IL-12p40, which may contribute to their tolero-
genic capacities. Both human and murine pDCs express CXCR3
and CXCR4, but human pDCs lack CCR9 expression, which could
be related to different maturation state (Drakes et al., 2009). CCR9
is expressed by human CD141+ DCs, which are considered to be
a homolog of mouse CD8+ DCs (Jongbloed et al., 2010; Poulin
et al., 2010). Yet, human CD141+ DCs do not express the same
TLR receptors as the mouse counterpart, thus have different sen-
sor functions (Kaisho, 2012). Skin resident CD141+ DCs are the
FIGURE 1 | Schematic representation of inflammatory vs. tolerogenic
DCs in vivo. Inflammatory DCs (red) differentiate from the immature
tissue-resident DCs and migrate to the lymph nodes, where they initiate
immune responses and instruct generation of the effector T cells (Teff).
Semi-mature DCs (green), which develop from the tissue-resident DCs in the
absence of danger and inflammatory signals, induce tissue-specific adaptive
regulatory T cells (pTreg). Dendritic cells in thymus play a role in the positive
and negative selection of naïve lymphocytes (Tnaive) and the induction of
naturally occurring regulatory T cells (tTreg). In mice, DCs seem to play
dispensable role in the thymus.
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major producer of IL-10, they induce T cell anergy and Tregs that
suppress skin inflammation. Interestingly, treatment with vitamin
D3 induces skin CD141+DC-like phenotype on human CD141−
DCs (Chu et al., 2012).
Manipulation of mouse DCs in vivo has shown therapeu-
tic potential to control immune response. Selective depletion of
mDCs sparing pDCs strongly attenuated autoimmune response
and reduced diabetes incidence in NOD mice (Nikolic et al.,
2005), and specific selective expansion of pDCs in vivo reduce
strong allergic responses (Kool et al., 2009). Depletion of a sub-
type of dermal DCs prevents differentiation of effector Th cells
and conferred resistance to EAE (King et al., 2010), and elim-
ination of Langerhans cells in the skin decreased the low-dose
contact hypersensitivity (Kel et al., 2010). A fine tuning between
CD8+ and CD8− cDCs that differentially stimulate Th1 vs. Th2
responses can regulate immunity, but the potential of DCs to stim-
ulate a particular type of helper T cells depends on the type of
the stimulatory signal they encounter. Immunoregulatory func-
tion of tolerogenic DCs in vivo is usually associated with their
incompletely differentiated state. It would be important to learn
how to prevent DCs in vivo from acquiring immunizing abilities
to avoid lack of control and offer safe therapeutic application in
humans.
IN VITRO GENERATED TOLEROGENIC DCs
Monocytes may be manipulated in vitro to generate DCs with
desired function and this has been investigated as immunother-
apy to a great extent (Palucka et al., 2003; Figdor et al., 2004;
Germain, 2010; Chia et al., 2012; Hong et al., 2012; Palucka and
Banchereau, 2012). Development of DCs in vitro under influ-
ence of GM-CSF and IL-4, reconstructs the sequence of events
established for peripheral tissue DCs although a direct approx-
imation of the in vitro generated DCs to an in vivo existing
subset is not possible. Tissue-resident DCs, like immature DCs
in culture, are characterized by high endocytic capacity and low
surface expression of major histocompatibility complex (MHC)
and co-stimulatory molecules. Danger signals or inflammation
encountered in the periphery triggers maturation of DCs, enabling
these to migrate to the lymph nodes and on their way acquire
all necessary tools to initiate an adequate response to phagocy-
tosed antigens. The maturation in vitro is induced by stimulating
DCs through pattern-recognition receptors (PRRs), CD40, or by
inflammatory cytokines.
Different approaches have been tested to induce tolerogenic
DCs in vitro and the features DCs have to fulfill are related
to the semi-mature phenotype, resistance to maturation, anti-
inflammatory cytokine profiles, and induction of specific T-cell
profiles. A tolerogenic state of DCs can be induced using several
pharmacological agents such as rapamycine, dexamethasone, Vit-
amin A, or Vitamin D, cytokines such as IL-10 or different growth
factors such as G-CSF, VEGF, VIP, and many others (Rutella et al.,
2006). Alternative approach has been tested as well using anti-
sense nucleotides to enforce stable immature phenotype of DCs
(Machen et al., 2004). These different tolerogenic DCs may share
certain features, such as semi-mature phenotype or the ability to
suppress allo-reactive response in the mixed leukocyte reaction
(MLR), yet many have specific features not shared by others. An
overview of phenotype and functional properties of different ex
vivo generated DCs is given in Table 1.
VITAMIN D AND DEXAMETHASONE MODULATED DCs
The active form of the natural immunomodulator Vitamin D
(i.e., 1,25(OH)2D3), alters the behavior of immune cells shifting T
lymphocytes into Tregs and modulating differentiation of human
peripheral blood monocytes (Piemonti et al., 2000; Griffin et al.,
2001; Adorini et al., 2003; Unger et al., 2009; Baeke et al., 2011),
or mouse bone marrow precursors (Griffin et al., 2001). Interest-
ingly, pDCs do not respond to the modulation by 1,25(OH)2D3
(Penna et al., 2007). Monocyte-derived DCs generated in the pres-
ence of 1,25(OH)2D3 (VD3-DC) show a semi-mature phenotype
with low MHC-class II expression, low activating co-stimulatory
molecules, and production of interleukin IL-10 instead of IL-12 in
the culture. In addition, VD3-DCs prevent priming of naïve CD4,
or CD8 T cells, induce apoptosis of effector T cells and induce
both allo- and auto antigen-specific Tregs from naïve CD4 T cells
(van Halteren et al., 2004; Unger et al., 2009; Kleijwegt et al., 2010,
2011, 2013). Similar potential to modulate monocyte develop-
ment into DCs with tolerogenic phenotype has been shown for
dexamethasone (Dex) (Matasic et al., 1999; Piemonti et al., 1999;
Rea et al., 2000; Chamorro et al., 2009; Unger et al., 2009). Like
VD3-DCs, Dex-DCs possess durable immaturity and a sustained
high IL-10 versus low IL-12 production, compared to non-treated
monocyte-derived DCs. In mice, application of Dex-DC prior to
allograft transplantation significantly prolonged the survival of
the grafts in an antigen-dependent fashion. Similar to VD3-DCs,
priming with Dex-DC leads to a decrease of IFN-γ-producing cells,
while increasing the number of IL-10 producing cells, which could
point to the induction of Tr1-like Tregs. However, Tregs induced
using Dex-DCs suppress in a bystander fashion independent of
antigen (Unger et al., 2009). 1,25(OH)2D3 and Dex used in com-
bination generate a third entity of tolerogenic DCs (Combi-DCs),
which share most features with VD3-DCs in terms of pheno-
type and function. Combined treatment with 1,25(OH)2D3 and
Dex enhanced the modulation of DCs, compared to either com-
pound alone with respect to surface marker expression, inhibition
of pro-inflammatory cytokine production, and attenuation of
T cell stimulatory capacity (Ferreira et al., 2012). Most impor-
tantly, Combi-DCs retain the capacity instilled by 1,25(OH)2D3
to induce antigen-specific Tregs. In vivo, combined-treated DCs
are more potent than IL-10-treated cells to suppress colitis in a
murine model (Pedersen et al., 2009).
To further investigate the effects of single vs. combined treat-
ment with 1,25(OH)2D3 or Dex as DC modulators, we performed
a 2D-DIGE analysis of protein profiles (Ferreira et al., 2012).
At the protein level, 1,25(OH)2D3 induced major changes in
proteins involved in iron metabolism, tricarboxylic cycle, and
the purine/pyrimidine metabolism/pentose phosphate pathway.
Dex alone changed proteins involved in the response to stress
in addition to several proteins included in the proteolysis and
the MHCII antigen presentation pathway. Combining both com-
pounds resulted in a unique protein profile of Combi-DCs,
although with a major impact of the 1,25(OH)2D3. Combi-
DCs had a profile closer related to VD3-DCs than to Dex-DCs,
which could be due to the experimental setup, since 1,25(OH)2D3
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treatment started at the beginning of DC differentiation while
Dex was added from day 3. Addition of Dex did not seem to
interfere with the effects of 1,25(OH)2D3 on protein expression
in DCs. The protein interaction networks and pathway analysis
demonstrated that combined treatment induces drastic changes in
metabolic pathways, which might affect the production of or the
response to ROS generation resulting in a Combi-DCs that are less
sensitive to death by nutrient starvation and have a robust antiox-
idative machinery possibly ensuring the survival of Combi-DCs
at the inflammation site in autoimmune diseases. Since genetic
polymorphisms may influence the response of immune cells to
1,25(OH)2D3 or Dex alone, these findings ensured us that com-
bining the two immunomodulators to overcome potentially insuf-
ficient modulation by a single agent is the way to go with respect
to clinical translation for immunomodulatory DC therapy.
MORPHOLOGY AND SURFACE PHENOTYPE OF VD3-TREATED
DCs: ACTIVATING VS. INHIBITORY CO-STIMULATORY
MOLECULES
Morphological features of 1,25(OH)2D3 and/or Dex modulated
DCs are different from non-treated monocyte-derived – moDCs.
Non-modulated moDCs form large clusters of non-adherent
cells with small dendrites, Dex-DCs are largely non-adherent
but show fewer small dendrites and form smaller clusters than
moDCs. In contrast, VD3-DCs and Combi-mDCs are adherent
with large spindle-shaped dendrites. Interestingly, this spindle-
shaped morphology was prominent when VD3- and Combi-DCs
were matured with LPS or CD40-L and less evident when DCs
were matured using the inflammatory cytokine cocktail (unpub-
lished observation). DCs treated with 1,25(OH)2D3 and/or Dex
maintain CD14 expression and do not express CD1a, although
they show high CD11c and DC-SIGN expression confirming that
they are DCs with a semi-mature phenotype and not macrophages
or arrested at monocyte stage (Unger et al., 2009; Ferreira et al.,
2012). Upon maturation, Combi-mDCs maintain high CD14
expression and high phagocytic capacity compared to moDCs,
possibly indicating a resistance to maturation. The functional con-
sequences of residual CD14 expression and phagocytosis remain
to be investigated.
Modulated DCs show lower expression of MHC-class II and
co-stimulatory molecules CD80 and CD86 when compared to
moDCs, upon maturation. VD3-DCs express higher levels of PD-
L1 and CD86 compared to Dex-DCs and Combi-DCs. However,
VD3-DCs and Combi-DCs show a similar ratio of PD-L1/CD86,
being higher than that of Dex-DCs. CD86 and PD-L1 belong
to the B7 family of receptors, which interact with the members
of the CD28 family of molecules (CD28, CTLA-4, ICOS, and
PD-1), generating potent activating or inhibitory signals in T
lymphocytes. CD28/B7 interactions mediate co-stimulation and
significantly enhance peripheral T-cell responses while CTLA-4
activation decreases T lymphocyte activity and limits the immune
response. Similarly,PD-1 receptor interactions with its ligands PD-
L1 and PD-L2 on DCs down-regulate T cell immune responses.
Despite these similarities, the regulatory roles of the CTLA-4 and
PD-1 pathways are different, which may be due to the differential
temporal and spatial expression patterns of their ligands. CTLA-4
signaling seems to be required early in the lymph node during
initiation of an immune response, while PD-1 pathway acts late
in the periphery to limit T-cell activity locally (Greenwald et al.,
2005). PD-L1 on VD3-DC is crucial for the acquisition of Treg
function by CD4+ T cells and blockade of PD-L1 on VD3-DC
during T cell priming generated Th1-like T cells incapable of
suppressing allo-reactive T-cell proliferation and producing IL-10
(Unger et al., 2009). These observations suggest that PD-L1/PD-1
interactions impair the generation of effector T cells in favor of
Treg formation. The underlying mechanism may involve reverse
signaling by PD-L1 into DC leading to decreased expression of the
positive co-stimulatory molecules CD80, CD86, and CD40 and
increased IL-10 production.
Inducible T cell costimulator (ICOS) has overlapping func-
tions with CD28 in early T-cell activation, and has emerged as an
important receptor in the immune system to regulate T-cell effec-
tor functions (de la Fuente et al., 2012). The ICOS/ICOSL pathway
is also involved in immune tolerance since ICOS regulates the
survival of both effector memory T cells and FoxP3+ Tregs dur-
ing homeostasis or antigen-specific immune response (Burmeister
et al., 2008). Modulated VD3- and Combi-DCs express ICOSL at
similar levels as the non-modulated moDC. The contribution of
ICOSL in the “downstream” tolerogenic mechanisms installed by
VD3-DCs will be discussed later in this review.
ANTI-INFLAMMATORY CYTOKINE PRODUCTION AND
RELATION TO “TOLEROGENIC” PHENOTYPE
A shift in cytokine production to predominant IL-10 and reduced
IL-12 production by 1,25(OH)2D3-treated DCs has been observed
in vitro in multiple studies with human as well as murine DCs
(Black et al., 1997; Ferreira et al., 2011). The turn-off signal for
the IL-12 and related cytokines could be IL-10, which blocks IL-12
synthesis, down-regulates the expression of co-stimulatory mole-
cules and potentiates tolerogenicity (Steinbrink et al., 1997; Rutella
et al., 2006). Proteomics analysis shows that 1,25(OH)2D3 and Dex
induce changes in DCs other than IL-10 production alone. Yet,
the contribution of IL-10 to the tolerogenic phenotype might be
larger than anticipated. TLR-activation induces a metabolic transi-
tion in DCs from oxidative phosphorylation to aerobic glycolysis
and IL-10 blocks this transition. By switching toward oxidative
phosphorylation, DCs are less reliant on glucose for survival and
function, and thus less sensitive to death by nutrient starvation
(Steinbrink et al., 1997; Rutella et al., 2006; Ferreira et al., 2009).
IL-10 is also important for the immunomodulatory effects of
VD3-DCs, attenuating Th1 driving forces and being protective in
settings of autoimmunity. Together with TGF-β, IL-10 expression
is a hallmark of the presence of regulatory T cells. However, IL-10
does not seem to be involved in the actual suppression by Tregs.
Tumor necrosis factor (TNF) is a pleiotropic cytokine most
known for pro-inflammatory (Th1) functions in multiple autoim-
mune diseases (Braun et al., 2002; Feldmann and Maini, 2003).
However, a beneficial effect of TNF in autoimmunity is also
acknowledged (Robinson et al., 2001; Ramos-Casals et al., 2008;
Ko et al., 2009; Tack et al., 2009). This dual role of TNF is seen in
other pathologic conditions such as infectious diseases and can-
cer (Gimenez, 2003; Calzascia et al., 2007). Diverse roles of TNF
in the immune response may be partly inferred by two forms of
TNF: a membrane-bound TNF (mTNF), which is cleaved from
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the membrane and released as a soluble cytokine (sTNF) (Black
et al., 1997). We demonstrated that VD3-DC produce increased
amounts of sTNF upon LPS stimulation. Yet, the expression of
mTNF distinguishes VD3-DCs from moDCs (Black et al., 1997;
Kleijwegt et al., 2010). We further demonstrated that mTNF is
essential for the induction of allo-specific suppressive T cells by
VD3-DCs through mTNF-TNFRII interaction, adding the role of
mTNF in the induction of immune tolerance to the list of multiple
functions of this cytokine.
Indoleamine 2,3-dioxygenase (IDO) and aryl hydrocarbon
receptor (AhR) have been implicated as negative regulators of
the inflammatory response by modulating the Th1/Th2 balance
(Negishi et al., 2005), and regulation of Treg and Th17 cell differ-
entiation (Quintana et al., 2008). We did not find evidence for the
contribution of these molecules in modulated DCs.
PRRs AND RESISTANCE TO MATURATION
Several synthetic TLR ligands activate DC subsets and promote
their adjuvant pro-inflammatory capacity, which can be a useful
tool in certain types of vaccines. DC express a broad repertoire of
TLRs with 10 members of the family described to date in human
(Medzhitov, 2001). TLRs trigger the signals that provide DC mat-
uration and the initiation of adaptive immune responses against
pathogens. The most known ligand for TLR4 is LPS (Medzhi-
tov, 2001), whereas TLR2 discriminates lipoproteins from Gram-
positive bacteria in association with TLR1 or TLR6 (Schwandner
et al., 1999; Takeuchi et al., 2002). In addition, self-proteins can be
recognized by both TLR2 and TLR4 (Asea et al., 2002).
The TLR repertoire on tolerogenic DCs modulated in vitro
with IL-10, dexamethasone, or Vitamin D appears similar to that
of immunogenic DCs, although with slight differences in the
expression levels of TLR2 and TLR4 (Chamorro et al., 2009).
However, tolerogenic DCs responded differently to TLR mediated
signals than immunogenic DCs showing partial maturation with
low to intermediate levels of CD80, CD86, and CCR7, reduced
ability to stimulate allogeneic T cells and secretion of the sup-
pressive cytokine IL-10 combined with very low production of
IL-12 or the related cytokines IL-23 and IL-27. The finding that
partially matured DCs respond to TLR2 stimulation with an anti-
inflammatory program could shed light on why patients with
severe sepsis undergo long-term systemic and local immunosup-
pression despite their increased TLR2 expression (Armstrong et al.,
2004), and how TLR2-derived signals from Candida albicans or
Schistosome infections drive immunosuppression by IL-10 pro-
duction and Treg induction (van der Kleij et al., 2002; Netea et al.,
2004). Indeed, TLR2 participates in the induction of peripheral
tolerance (Dillon et al., 2006), in the promotion of T regula-
tory responses leading to protection against autoimmune diseases
in vivo (Manicassamy et al., 2009). Thus, the TLR2 up-regulation
and activation on VD3- and Dex-treated DCs might enhance their
tolerogenic properties.
In vivo application of DCs in patients faces possible pro-
inflammatory triggering and the tolerogenic DC vaccine should
not divert into pro-inflammatory DC upon injection. Preserva-
tion of tolerogenic function in the settings of an activated immune
system (resistance to maturation) is therefore considered a prereq-
uisite of tolerogenic potential for immunomodulatory vaccines.
Pro-inflammatory DC maturation is induced when DCs sense
microbes through PRRs, interact with T cells (through CD40)
or get exposed to inflammatory cytokines. We mimicked in vivo
DC activation by re-stimulating matured tolerogenic DCs with
LPS, CD40-L, or the cocktail of cytokines (IL-6, TNF, IL-1β, and
PGE2), and demonstrated that DCs modulated with Vitamin D
alone or combined with dexamethasone maintained a stable regu-
latory phenotype, IL-10 production, and low stimulation of allo-
geneic T cells upon repeated maturation with either LPS, CD40-L,
or cytokine mix. Similarly, a study comparing resistance to re-
stimulation with LPS of the rapamycin-, dexamethasone-, and
Vitamin D-treated DCs, demonstrated a stable high IL-10 and no
IL-12/IL-23 production (Naranjo-Gomez et al., 2011).
MODULATED DC ARE EQUIPPED TO MIGRATE TO INFLAMED
AND SECONDARY LYMPHOID TISSUES – CHEMOKINE
PRODUCTION UPON TLR TRIGGERING
To be effective in silencing reactive T cells or inducing tissue-
specific Tregs in vivo, it is of key importance that injected modu-
lated DCs reach lymphoid tissues or the inflamed site. We therefore
examined the expression of several chemokine receptors. Imma-
ture Dex-, VD3-, and moDCs expressed significant levels of CCR4
and CCR5, but no CCR7 (Unger et al., 2009). Upon maturation,
CCR4 and CCR5 were down-regulated, whereas CCR7 was up-
regulated by all DCs indicating the ability to migrate to secondary
lymphoid tissues. CXCR3 was expressed on the surface of the
modulated DCs, which may guide these cells to the inflammatory
lesion in the pancreas to counteract autoreactive T cells around
the distressed islets (van Halteren et al., 2005; Roep et al., 2010).
PREVENTING PRIMING OF NAÏVE T CELLS – NEGLECTION OR
ACTIVE INHIBITION?
Schematic representation of molecules involved in the tolerogenic
function of VD3-modulated DCs is given in Figure 2. VD3-DC
and Combi-DC impair priming of naïve CD4 and CD8 T cells
(Unger et al., 2009; Kleijwegt et al., 2013). Naïve T cells require anti-
gen recognition, co-stimulation, and activating cytokines (mostly
IL-12) to become effector T cells. VD3-DC and Combi-DCs
express lower levels of co-stimulatory molecules and IL-12, pro-
viding incomplete stimulation to T cells. However, our data show
that besides hampered stimulation, an active repression prevents
priming of naïve T cells (Kleijwegt et al., 2013). Combi-DCs pro-
duce TNF and TGF-β (Chamorro et al., 2009; Kleijwegt et al.,
2010), but neither of these cytokines contributed to the obstructed
priming of CD8 T cells. Since Combi-DCs interfere with priming
only when they present the cognate antigen to the T cell, mecha-
nisms related to TCR signaling may be responsible for this effect.
This could happen through failing trans-presentation of IL-15, IL-
2 (Combi-DCs lack CD25 expression), or high ILT-3 expression,
as demonstrated in other systems (Chamorro et al., 2009; Frasca
et al., 2010; Kleijwegt et al., 2010; Huntington et al., 2011).
KILLING OF T CELLS BY TOLEROGENIC DCs – THE STORY OF
MR. AND MS. SMITH
Tolerogenic mechanisms of VD3-DCs include deletion of naïve T
cells since the cell numbers after the co-culture with VD3-DCs are
reduced compared to the cultures with non-treated moDCs. The
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FIGURE 2 | Molecules involved in the tolerogenic function of Vitamin
D-modulated DCs (VD3-DCs). VD3-DC express MHC class II in
combination with low co-stimulatory molecules (CD80/86) and high
expression of PD-L1, which enable antigen-dependent elimination of Th1
effector T cells and induction of antigen-specific adaptive regulatory T cells
(iTregs). VD3-DCs express additional regulatory molecules: TLR2, ILT-3, and
membrane-bound TNF (mTNF), and produce IL-10, which potentiate the
tolerogenic function of VD3-DCs. VD3-DCs also express chemokines,
which enable the migration both to lymph nodes (CCR7) and to the site of
inflammation (CXCR3).
ability of DCs to kill target cells that could serve in anti-tumor
immunity or T-cell killing in autoimmunity and transplantation
has been described (Chauvin and Josien, 2008). A recent study in
pulmonary tuberculosis patients confirms the cytotoxic activity
of DCs as a mechanism of negative regulation of T lymphocytes
(Sakhno et al., 2012). In case of VD3-DCs, this action is antigen-
dependent but not restricted to naïve T cells since VD3-DCs also
block IFNγ and IL-10 production and induce active killing of a
diabetogenic Th1 clone in an antigen-specific manner (van Hal-
teren et al., 2002). When interacting with memory CD8 T cells,
Combi-DCs initially expand this cell pool, which collapses after the
subsequent re-stimulation (Kleijwegt et al., 2013). This is caused
by an increased cell death in the second co-culture. To test whether
memory CD8 T cells undergo increased apoptosis in the second
culture due to the primary interaction with tolerogenic DCs, mem-
ory CD8 T cells initially stimulated with tolerogenic DCs were
subsequently re-stimulated with moDCs. This only partially res-
cued CD8 T cells from the collapse in the second culture, implying
that during the first stimulation tolerogenic DCs endorse mem-
ory CD8 T cells with features underlying their subsequent ceased
growth. The depletion of CD8 T cells by Combi-DCs could result
from a combined action of the withdrawal of positive signals (co-
stimulation and cytokines) and inhibition by secreted regulatory
factors (such as IL-10 and TGF-β), creating a less favorable envi-
ronment for cytotoxic T cell survival and expansion (Bots et al.,
2007; Toda et al., 2011). This process could also involve expres-
sion of CXCR3 facilitating memory degeneration, inhibition of
autocrine IL-2 production, or induction of pro-apoptotic signals
as described in other models (Kurachi et al., 2011; Takata et al.,
2012).
The finding that tolerogenic DCs induce elimination of effector
CD8 T cells initially appeared to offer a valuable tool to tackle the
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destructive forces such as autoreactive CD8 T cells in the pancreas
of patients with type 1 diabetes by loading diabetogenic MHC-
class I peptides onto tolerogenic DCs. However, a draw-back in
this respect was our finding that antigen-loaded tolerogenic DCs
were eliminated by the cytotoxic CD8 T cells through a Granzyme
B-dependent mechanism (Kleijwegt et al., 2013). DCs have the
ability to protect themselves from being killed using protective
molecules like Serpin 9 or Cathepsin B (Bots et al., 2007) or by
up-regulation of antiapoptotic proteins, such as Bcl-xL (Gutier-
rez et al., 2007). Indeed, tolerogenic DCs were more protected
from killing than moDCs or B cells. Yet, in order to preserve the
immunomodulatory action of tolerogenic vaccine on other cells
types, loading of MHC-class I epitopes does not appear to add to
MHC-class II epitopes on tolerogenic DCs.
VITAMIN D3-TREATED DCs INDUCE INFECTIOUS TOLERANCE
THROUGH ANTIGEN-SPECIFIC TREGS
As established above, VD3- and Combi-DCs induce Tregs that
suppress in an antigen-dependent manner, which is specialized
feature of 1,25(OH)2D3-treated DCs. Rapa-DC-primed T cells
exhibit reduced alloproliferation along with a concomitant expan-
sion of naturally occurring tTregs (Kang et al., 2008; Simonetta
et al., 2010), and Dex-DCs induce adaptive Tregs that suppress in
an antigen-independent fashion (Unger et al., 2009). PD-L1 and
mTNF play important roles in the mechanisms by which VD3-
DCs induce allo-reactive or proinsulin specific Tregs (Kleijwegt
et al., 2011).
Induced (adaptive) proinsulin-peptide specific Tregs (iTregs)
suppress diabetogenic Th1 cells via linked suppression and do not
need IL-10 or TGF-β to perform their suppressive functions (Klei-
jwegt et al., 2011). Tregs may exert their antigen-specific function
via cytolysis of the APCs, metabolic disruption, or by modu-
lating the immunogenic function of DCs (Vignali et al., 2008).
We have demonstrated that iTregs induced by VD3-DC perform
two of three described functions and the contribution of iTregs
to metabolic disruption remains to be investigated. iTregs re-
educate pro-inflammatory moDCs in an antigen-specific manner
by changing the phenotype (@DC), which differs from VD3-DCs
used to generate iTregs: VD3-DCs have low CD80 and CD86,
high ILT-3 and PD-L1, low ICOSL, and no B7-H3 expression
(Unger et al., 2009), whereas @DCs retain high expression of
HLA-DR and co-stimulatory molecules CD80 and CD86, and low
expression of inhibitory molecules PD-L1, ILT-3, and ILT-4 (Klei-
jwegt et al., 2011). The difference in phenotype may originate
in the mode of modulation: VD3-DCs result from modulation
of monocytes with vitamin D3 during differentiation, whereas
iTregs alter fully differentiated mature moDCs into @DC. The
specific alteration of antigen-bearing moDCs, which persisted
upon removal of iTregs, was characterized by up-regulation of
B7-H3 and ICOSL. Both molecules are involved in immune reg-
ulation: B7-H3 preferentially dampens Th1-mediated responses
(Suh et al., 2003), whereas ICOSL promotes IL-10 secretion by
T cells (Witsch et al., 2002) and induces Tr1 cells that produce
IL-10 and inhibit experimental airway inflammation in mice
(Akbari et al., 2002; Conrad et al., 2012). The induction of IL-
10–producing T cells by human @DCs was indeed mediated
through ICOSL.
Infectious tolerance is a process in which a tolerance-inducing
state is transferred from one cell population to another and
is supported by different mechanisms, including IL-35, TGF-β
production, or essential amino acid-depleting enzymes (Jonuleit
et al., 2002; Cobbold et al., 2009; Collison et al., 2010). VD3-
DCs transfer tolerogenic properties to mature pro-inflammatory
DC via iTregs, which operate in an antigen-dependent manner
(modeled in Figure 3). When applied as an intervention ther-
apy, this implies that Tregs specific for a single auto antigen
FIGURE 3 | VD3-DCs confer infectious tolerance through
antigen-specific adaptive regulatoryT cells (iTregs). Vitamin D
modulates monocytes to differentiate into tolerogenic DCs (VD3-DCs),
which induce iTregs. This process is mediated by PD-L1 and
membrane-bound TNF (mTNF). iTregs, in turn, functionally modify
pro-inflammatory moDCs to become anti-inflammatory DCs (@DCs),
which present the cognate antigen of iTregs. As a consequence, @DCs
upregulate inhibitory receptors ICOSL and B7-H3, lose the capacity to
stimulate Th1 responses and instead induce IL-10–producing T cells from
the naive T cell pool.
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generated by tolerogenic DCs could alter other local DCs that
subsequently reduce autoimmune responses to a diverse range of
tissue-associated antigens.
Interplay between DCs and Tregs is essential for the immune
tolerance since a direct correlation between DC numbers and Treg
cells has been found as part of a feedback-control mechanism
(Darrasse-Jeze et al., 2009). DCs promote and enhance the sup-
pression by Treg cells and in turn, Tregs condition other DCs to
upregulate inhibitory molecules and modulate effector responses.
Instillation of VD3-DCs in this loop would support the regula-
tory and anti-inflammatory forces in the setting of autoimmune
response that has escaped the regular control.
CONCLUDING REMARKS – TOWARD A TOLEROGENIC
IMMUNOTHERAPY WITH DCs
Getting hold of a method to obtain efficient tolerogenic DCs in
the clinical setting is a holy grail that will enable reshaping the
immune response to particular needs. This may be accomplished
using ex vivo modulated DCs. These cells might not be the same as
tolerogenic DCs that exist in vivo and might need to be repetitively
injected to achieve a continuous tolerogenic treatment. However,
the ex vivo generation of tolerogenic DCs permits the propagation
of sufficient amounts of cells in controlled conditions and load-
ing with an antigen of choice thereby enabling targeted tolerizing
immunotherapies.
Tolerogenic DCs modulated using the biologically active form
of vitamin D (1,25(OH)2D3) are a promising tool for tolerance
induction in clinic. Years of investigation of these tolerogenic
DCs have helped understand the contribution of different PRRs
and secondary signals in facilitating tolerogenic DCs to prime
antigen- and tissue-specific Tregs by mechanisms such as linked
suppression and infectious tolerance. These learned lessons helped
understanding how a cross-talk between DCs and T cells trans-
lates into immune regulation and may support finding therapies
with small molecules that recapitulate the mode of action of cell
therapy.
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